Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: J Neuroimmunol. 2012 Feb 25;245(1-2):1–7. doi: 10.1016/j.jneuroim.2012.01.005

Figure 1. BBI suppresses EAE in C57BL/6 mice.

Figure 1

(A) C57BL/6 mice were immunized with MOG35-55 and treated with BBI (1 mg/day, n=10 or 3 mg/day, n=4) or PBS (n=11) by oral gavage from the day of immunization until the end of the experiment; mice were scored daily for clinical disease. (B) On days 7, 14 and 21 p.i., mice were sacrificed and cells from CNS isolated and counted. Data are shown as percentage relative to the cell number obtained from PBS-treated mice. (C) On day 21 p.i., draining LN cells were harvested and stimulated with anti-CD3/CD28 for 3 days; thereafter supernatants were analyzed for IL-10 by ELISA. P values refer to the comparison between BBI- vs. PBS-treated groups. Data are representative of three independent experiments.